Drug intelligence / Profile preview

PMB212

Development stage: Preclinical
Lead developer: PiMedBio
Modality: Small Molecules
Administration: Intravenous Infusion[3]

Overview

PMB212 is a first-in-class cancer stemness blocking agent developed by Pimedbio. It is designed to inhibit a novel, undisclosed target protein that regulates multiple major pathways associated with the induction and enhancement of cancer stemness, including Wnt, Notch, Hedgehog, STAT3, NF-kB, BMI-1, and Hippo pathways. By blocking these pathways and downregulating cancer stemness markers and ABC transporters, PMB212 aims to reduce tumor resistance and recurrence. Preclinical studies have demonstrated anti-cancer efficacy in animal models[2][3]. The drug is being developed for the treatment of neoplasms (cancers), particularly those resistant to conventional therapies[1][2][3].

Other names: Cancer stemness blocking agent (PMB212)

Beyond the preview

Go deeper on PMB212.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PMB212.

Explore the full profile